Mesnum
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
SummaryThirty-two patients with advanced cancer were treated in a phase I–II trial with ifosfamide plus mesnum. At doses up to…
Ifosfamide (50-60 mg/kg of body weight, Days 1-5) and mesnum (10-12 mg/kg of body weight, Days 1-5) were given to 15 patients…
Ifosfamid is an alkylating cytostatic agent which appears to differ in its clinical spectrum from the chemically similar…
In an open multicenter phase III trial, prophylaxis of the urinary tract with sodium 2-mercaptoethanesulfonate (Mesnum) was…